Differential effects of vildagliptin and glimepiride on glucose fluctuations in patients with type 2 diabetes mellitus assessed using continuous glucose monitoring von He, Y. L., Foteinos, G., Neelakantham, S., Mattapalli, D., Kulmatycki, K., Forst, T., Taylor, A.

Volltext

Drug‐disease interactions: reduced β‐adrenergic and potassium channel antagonist activities of sotalol in the presence of acute and chronic inflammatory conditions in the rat von Kulmatycki, Kenneth M, Abouchehade, Kassem, Sattari, Saeed, Jamali, Fakhreddin

Volltext

WCN23-0372 ASSESSMENT OF DRUG INTERACTIONS WITH IPTACOPAN von SCHMOUDER, R., Shah, B., Taylor, A., Nidamarthy, P.K., Kulmatycki, K.

Volltext

Disposition of loratadine in healthy volunteers von Ramanathan, R., Reyderman, L., Kulmatycki, K., Su, A.-D., Alvarez, N., Chowdhury, S. K., Alton, K. B., Wirth, M. A., Clement, R. P., Statkevich, P., Patrick, J. E.

Volltext

Efficacy and Safety of the CFTR Potentiator Icenticaftor (QBW251) in COPD: Results from a Phase 2 Randomized Trial von Rowe, Steven M, Jones, Ieuan, Dransfield, Mark T, Haque, Nazmul, Gleason, Stephen, Hayes, Katy A, Kulmatycki, Kenneth, Yates, Denise P, Danahay, Henry, Gosling, Martin, Rowlands, David J, Grant, Sarah S

Volltext

WCN23-0371 ABSORPTION AND DISPOSITION OF A FIRST-IN-CLASS ALTERNATIVE COMPLEMENT PATHWAY FACTOR B INHIBITOR: IPTACOPAN von SCHMOUDER, R., Shah, B., Hackling, M., James, A.D., Nidamarthy, P.K., Kulmatycki, K.

Volltext

THERAPEUTIC RELEVANCE OF ALTERED CYTOKINE EXPRESSION von Kulmatycki, Kenneth M., Jamali, Fakhreddin

Volltext

Efficacy and Safety of the CFTR PotentiatorIcenticaftor (QBW251) in COPD: Results from a Phase 2 Randomized Trial von Rowe SM, Jones I, Dransfield MT, Haque N, Gleason S, Hayes KA, Kulmatycki K, Yates DP, Danahay H, Gosling M, Rowlands DJ, Grant SS

Volltext

A51 BRONCHIECTASIS: CLINICAL AND EPIDEMIOLOGIC STUDIES: Qbw251 Is A Safe And Efficacious Cftr Potentiator For Patients With Cystic Fibrosis von Kazani, S, Alcantara, J, Debonnett, L, Doucet, J, Jones, I, Kulmatycki, K, Machineni, S, Mostovy, L, Nicholls, I, Vegesna, R, Verheijen, J, Rowlands, D J

Volltext

L’inhibiteur oral du facteur b du complément iptacopan chez les patients (pts) atteints d’hémoglobinurie paroxystique nocturne (hpn) avec hémolyse active malgré un traitement anti-... von Peffault De Latour, R., Roth, A., Soret, J., Frieri, C., Sicre De Fontbrune, F., Marano, L., Alashkar, F., Benajiba, L., Marotta, S., Kulmatycki, K., Nidamarthy, P.K., Fagan, N., Junge, G., Risitano, A.

Volltext

Drug disease interactions: role of inflammatory mediators in disease and variability in drug response von Kulmatycki, Kenneth M, Jamali, Fakhreddin

Volltext

Grapefruit juice and orange juice effects on the bioavailability of nifedipine in the rat von Grundy, John S., Eliot, Lise A., Kulmatycki, Ken M., Foster, Robert T.

Volltext

Grapefruit juice and orange juice effects on the bioavailability of nifedipine in the rat von Grundy, John S., Eliot, Lise A., Kulmatycki, Ken M., Foster, Robert T.

Volltext

Dose-Exposure-Response Relationships of Biomarkers and Efficacy Measures with Iptacopan, a Complement Factor B Inhibitor, in Patients (pts) with Paroxysmal Nocturnal Hemoglobinuria... von Risitano, Antonio, Peffault de Latour, Régis, Yap, Eng Soo, Wong, Lily LL, Ko, Bor-Sheng, Yoon, Sung-Soo, Roeth, Alexander, Baltcheva, Irina, Milojevic, Julie, Fagan, Niamh, Kulmatycki, Kenneth, Nidamarthy, Prasanna K, Junge, Guido, Jang, Jun Ho

Volltext

Iptacopan, a Novel Oral Complement Factor B (FB) Inhibitor, Significantly Reduces Proteinuria and C3 Deposit Scores in Native and Transplanted Kidneys C3 Glomerulopathy (C3G) Patie... von Wong, Edwin K., Nester, Carla M., escribano, Teresa Cavero, Karras, Alexandre, Lequintrec-Donnette, Moglie, Lightstone, Liz, Eisenberger, Ute, Soler, Maria Jose, Biondani, Andrea, Chaperon, Frederique, Kulmatycki, Kenneth M., Milojevic, Julie M., Nidamarthy, Prasanna Kumar, Webb, Nicholas, Junge, Guido, Remuzzi, Giuseppe

Volltext